Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H2158 for the Treatment of Chronic Hepatitis B Virus Infection
09 juil. 2020 08h00 HE
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., July 09, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 juil. 2020 16h30 HE
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., July 02, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection
25 juin 2020 08h00 HE
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Preclinical Data from Assembly Biosciences’ Immuno-Oncology Microbiome Program Featured at AACR’s Virtual Annual Meeting II
22 juin 2020 08h45 HE
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Regains Worldwide Rights to Microbiome Gastrointestinal Development Programs
18 juin 2020 16h01 HE
|
Assembly Biosciences, Inc.
-- Process to explore strategic alternatives underway -- SOUTH SAN FRANCISCO, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology...
Assembly Biosciences Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
01 juin 2020 16h18 HE
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Announces Management Transition
27 mai 2020 08h00 HE
|
Assembly Biosciences, Inc.
-- Expert Virologist and Biologist William Delaney, PhD joins as Chief Scientific Officer, Virology -- -- EVP and CSO of Virology Operations Richard Colonno, PhD to retire -- SOUTH SAN FRANCISCO,...
Assembly Biosciences to Present During the Jefferies Virtual Healthcare Conference
26 mai 2020 08h00 HE
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 26, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis...
Assembly Biosciences Announces Move to Virtual-Only Annual Meeting of Stockholders on June 11, 2020
19 mai 2020 16h05 HE
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 19, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) today announced that it will hold its 2020 Annual Meeting of Stockholders (Annual Meeting)...
Assembly Biosciences Reports Updates on Corporate Progress and First Quarter 2020 Financial Results
07 mai 2020 16h05 HE
|
Assembly Biosciences, Inc.
-- Advancing the development of three clinical-stage core inhibitor candidates in HBV portfolio ---- Cash position of $249 million projected to fund operations into 2022 ---- Company to host HBV...